Przejdź do głównego menu Przejdź do sekcji głównej Przejdź do stopki
Baner text

Tom 28 Nr 4 (2018)

Articles

Ostropest plamisty (Silybum marianum [L .] Gaertn.) – fitochemia i efekty terapeutyczne

DOI: https://doi.org/10.24326/ah.2018.4.2
Przesłane: grudnia 31, 2018
Opublikowane: 2018-12-31

Abstrakt

Ostropest plamisty (Silybum marianum (L.) Gaertn.) jest obecnie jednym z ważniejszych gatunków roślin leczniczych uprawianym na plantacjach zielarskich. Surowcem zielarskim ostropestu jest owoc (Silybi mariani fructus) zawierający kompleks flawonolignanów określanych jako sylimaryna. Sylimaryna wykazuje działanie ochronne i regenerujące względem uszkodzonych komórek wątroby. Działanie ochronne sylimaryny wiąże się z jej aktywnością antyoksydacyjną, przeciwzapalną, przeciwwirusową, a także odtruwającą. Związek ten wpływa również na syntezę RNA i DNA. Sylimaryna jest obecnie szeroko stosowana jako środek terapeutyczny w leczeniu wielu ostrych i przewlekłych chorób wątroby. Ostatnie badania dowodzą, że sylimaryna jest skutecznym lekiem przeciwwirusowym w przypadku wirusa zapalenia wątroby typu C (HCV). Wskazywana jest także jako obiecujący środek przeciwnowotworowy, przeciwcukrzycowy i nefroochronny. W lecznictwie i kosmetologii zastosowanie ma także olej z nasion ostropestu, bogaty w cenne kwasy tłuszczowe, fosfolipidy i witaminę E.

Bibliografia

  1. Abdelazim S., 2017. Effect of silymarin as natural antioxidants and antimicrobial activity. Nutri. Food Sci. Int. J. 2(3), 555589, DOI: 10.19080/NFSIJ.2017.02.555589.
  2. Abdelhalim M.A., Jarrar B.M., 2012. Histological alterations in the liver of rats induced by different gold nanoparticle sizes, doses and exposure duration. J. Nanobiotechnol. 10(5), DOI: 10.1186/1477-3155-10-5.
  3. Abenavoli L., Capasso R., Milic N., Capasso F., 2010. Milk thistle in liver diseases: past, present, future. Phytother. Res. 24(10), 1423–1432.
  4. AbouZid S.F., Chen S.N., Pauli G.F., 2016. Silymarin content in Silybum marianum populations growing in Egypt. Ind. Crops Prod. 83, 729–737, DOI: 10.1016/j.indcrop.2015.12.012.
  5. Ahmad N., Perveen R., Jamil M., Naeem R., Ilyas M., 2015. Comparison of antimicrobial properties of Silybum marianum (L) collected from ten different localities of Khyber Pakhtunkhwa Pakistan and diversity analysis through RAPDs pattern. Int. J. Plant Sci. Ecol. 1(6), 2015, 241–245.
  6. Ahmadzadeh A., Aghababaei M.R., Allameh Z., Zarchii S.R., Fazilati M., 2017. The impact of silymarin extract on oxidative stress induced by gold nanoparticles. Biomed. Res. 28(14), 6144–6150.
  7. Akramas L., Leonavičienė L., Vasiliauskas A., Bradūnaitė R., Vaitkienė D., Zabulytė D., Normantienė T., Lukošius A., Jonauskienė I., 2015. Anti-inflammatory and anti-oxidative effects of herbal preparation EM 1201 in adjuvant arthritic rats. Medicina 51, 368–377.
  8. Alemardan A., Karkanis A., Salehi R., 2013. Breeding objectives and selection criteria for milk thistle (Silybum marianum [L.] Gaertn.) improvement. Not. Bot. Horti. Agrobo. 42(2), 340–347.
  9. Alikaridis F., Papadakis D., Pentelia K., Kephalas T., 2000. Flavonolignan production from Silybum marianum transformed and untransformed root cultures. Fitoterapia 71, 379–384.
  10. Aliyas I.M., 2017. Wild milk thistle unique fatty plant. Int. J. Sci. Res. (IJSR) 6(1), 1227–1229, DOI: 10.21275/25121602.
  11. Amado N., Fonseca B., Cerqueira D., Neto V., Abreu J., 2011. Flavonoids: potential beta-catenin signalling modulators in cancer. Life Sci. 89, 545–554.
  12. Amirghofran Z., Azadbakht M., Karimi M.H., 2000. Evaluation of the immunomodulatory effects of five herbal plants. J. Ethnopharmacol. 72, 167–172.
  13. Andrzejewska J., Skinder Z., 2006. Ostropest plamisty – uwagi o nazewnictwie, substancjach czynnych i rozwoju rośliny. Acta Sci. Pol., Agricultura 5(1), 5–10.
  14. Andrzejewska J., Sadowska K., Mielcarek S., 2011. Effect of sowing date and rate on the yield and flavonolignan content of the fruits of milk tistle (Silybum marianum L. Gaertn.) grown on light soil in a modern climate. Int. Crops Prod. 33(2), 462–468.
  15. Anthony K.P., Saleh M.A., 2012. Chemical profiling and antioxidant activity of commercial milk thistle food supplements. J. Chem. Pharm. Res. 4, 4440–4450.
  16. Anthony K.P., Saleh M.A., 2013. Free radical scavenging and antioxidant activities of silymarin components. Antioxidants 2, 398–407.
  17. Asghari-Zakaria R., Panahi A., Sadeghizadeh M., 2008. Comparative study of chromosome morphology in Silybum marianum. Cytol. 73(3), 327–332.
  18. Awan A., Wollmann J., Rathay P., Mersinger R., 2014. Neue Erkenntnisse zur Wirkung der Mariendistel. Hevert-Newsletter 1, 5–8.
  19. Azaizeh H., Fulder S., Khalil K., Said O., 2003. Ethnobotanical knowledge of local Arab practitioners in the Middle Eastern region. Fitoterapia 74, 98–108.
  20. Bacler-Żbikowska B., Drobnik J., 2011. Komentarz botaniczny do roślin leczniczych i surowców roślinnych wymienionych w Farmakopei Polskiej VIII. Część II. Ann. Acad. Med. Siles. 65(1–2), 61–71.
  21. Bajwa A., Tariq S., Yuchi A., Hafeez R., Arshad A., Zaman M., Aqeel T., Mushta M.N., 2016. Evaluation of Anti-bacterial Activity of Silybum marianum against Pathogenic and Resistant Bacteria. Europ. J. Med. Plant. 13(4), 1–7.
  22. Balian S., Ahmad S., Zafar R., 2006. Antiinflammatory activity of leaf and leaf callus of Silybum marianum (L.) Gaertn. in albino rats. Indian J. Pharmacol. 38(3), 213–214.
  23. Baranowska B., Kurzepa K., Marczak E., Szczucińska A., Lipkowski A., 2003. Utylizacja odpadu nasion ostropestu plamistego II. Biologicznie czynne peptydy z odpadu nasion ostropestu plamistego. Rośl. Oleiste 24, 725–732.
  24. Bhatia N., Zhao J., Wolf D., Agarwal R., 1999. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett. 147, 77–84.
  25. Bhattacharya S., 2011. Phytotherapeutic properties of milk thistle seeds: An overview. J. Adv. Pharm. Educ. Res. 1, 69–79.
  26. Bijak M., 2017. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.) – chemistry, bioavailability, and metabolism. Molecules 22, 1942, DOI: 10.3390/ molecules22111942.
  27. Bokemeyer C., Fels L., Dunn T., Voigt W., Gaedeke J., Schmoll H., Stolte H., Lentzen H., 1996. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br. J. Canc. 74, 2036–2041.
  28. Breschi M., Martinotti E., Apostoliti F., Nieri P., 2002. Protective effect of silymarin in antigen challenge- and histamine-induced bronchoconstriction in in vivo guinea-pigs. Eur. J. Pharm. 437, 91–95.
  29. Carrier D., Crowe T., Sokhansanj S., Wahab J.,Barl B., 2003. Milk thistle, Silybum marianum (L.) Gaertn., flower head development and associated marker compound profile. J. Herb. Spec. Med. Plant. 10(1), 65–74.
  30. Chambreau D., Maclaren P., 2007. Got milk thistle? An adaptive management approach to eradicating milk thistle on dairies in King country, Washington state. In: Meeting the Challenge: Invasive Plants in Pacific Northwest Ecosystems, 83–84.
  31. David Y., Lee W., Yanze L., 2003. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (Milk Thistle). J. Nat. Prod. 66, 1171–1174.
  32. Deep G., Agarwal R., 2010. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 29(3), 447–63.
  33. Dehmlow C., Erhard J., De Groot H., 1996. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23(4), 749–754.
  34. Dixit N., Baboota S., Kohli K., Ahmad S., Ali J., 2007. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Ind. J. Pharmacol. 39(4), 172–179.
  35. Dvorak Z., Kosina P., Walterova D., Simanek V., Bachleda P., Ulrichova J., 2003. Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol. Lett. 137, 201–212.
  36. Dyduch J., Najda A., 2007. The evaluation of the milk thistle (Silybum marianum Gaertn.) fruit quality depending on the pericarp colour. Herba Pol. 53(3), 331–336.
  37. Elsaesser A., Howard C.V., 2012. Toxicology of nanoparticles. Adv. Drug Deliver. Rev. 64, 129–137.
  38. El-Samaligy, M.S., Afifi, N.N., Mahmoud, E.A., 2006. Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int. J. Pharm. 319, 121–129.
  39. Eo H.J., Park G.H., Song H.M., Lee J.W., Kim M.K., Lee M.H., Lee J.R., Koo J.S., Jeong J.B., 2015. Silymarin induces cyclin D1 proteasomal degradation via its phosphorylation of threonine-286 in human colorectal cancer cells. Int. Immunopharmacol. 24, 1–6.
  40. Farmakopea Polska XI, 2017. PTF, Warszawa.
  41. Fathi-Achachlouci B., Azadmard-Damirchi S., 2009. Milk thistle seed oil constituents from different varieties grown in Iran. J. Am. Oil Chem. Soc. 86, 643–649.
  42. Fraschini F.., Dermartini G., Esposti D., 2002. Pharmacology of silymarin. Clin. Drug. Invest. 22, 51–65.
  43. Galhardi F., Mesquita K., Monserrat J.M., Barros D.M., 2009. Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain. Food Chem. Toxicol. 47, 2655–2660.
  44. Gandhi A., Dutta A., Pal A., Bakshi P., 2012. Recent trends phytosomes for delivering herbal extract with improved bioavailability. J. Pharmacogn. Phytochem. 1(4), 6–14.
  45. Gazak R., Walterova D., Kren V., 2007. Silybin and silymarin – new and emerging applications in medicine. Curr. Med. Chem. 14(3), 315–338.
  46. Gharagozloo M., Velardi E., Bruscoli S., Agostini M., Di Sante M., Donato V., 2010. Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-κB activity and IL-2 production. Pharmacol. Res. 61(5), 405–409.
  47. Giuliani C., Tani C., Bini L.M., Fico G., Colombo R., Martinelli T., 2018. Localization of phenolic compounds in the fruits of Silybum marianum characterized by different silymarin chemotype and altered colour. Fitoterapia 130, 210–218.
  48. Glinka R., Góra J., 2000. Związki naturalne w kosmetyce. Zastosowanie oleju z ostropestu plamistego w kosmetyce. Wyd. Warsaw Vioce.
  49. Greenlee H., Abascal K., Yarnell E., Ladas E., 2007. Clinical applocations of Silybum marianum in oncology. Integr. Cancer Ther. 6(2), 158–165.
  50. Hadaruga D.I., Hadaruga N.G., 2009. Antioxidant activity of hepatoprotective silymarin and Silybum marianum L. extract. Chem. Bull. “Politehnica” Univ. (Timisoara) 54(68), 104–107.
  51. Hadolin M., Skerget M., Knez Z., Bauman D., 2001. High pressure extraction of vitamin E-rich oil from Silybum marianum, Food Chem. 74, 355–364.
  52. Hagymasi K., Kocsis I., Lugasi A., Feher J., Blazovivs A., 2002. Extrahepatic biliary obstruction: Can silymarin protect liver function? Phytother. Res. 16, 78–80.
  53. Hajighasemlou S., Farajollahi M., Alebouyeh M., Rastegar H., Manzari M.T., Mirmoghtadaei M., Moayedi B., Ahmadzadeh M., Kazemi M., Parvizpour F., Gharibzadeh S., 2014. Study of the effect of silymarin on viability of breast cancer cell lines. Adv. Breast Cancer Res. 3, 100–105.
  54. Harrabi S., Romdhane H., Daassa H., Fellah H., 2015. Fatty acid and triacylglycerol compositions of milk thistle seeds growing wild in Tunisia (Silybum marianum L.). Acta Aliment. 44(2), 304–310.
  55. Harrabi S., Curtis S., Hayet F., Mayer P.M., 2016. Changes in the sterol compositions of milk thistle oil (Silybium marianum L.) during seed maturation. Grasas Aceites 67(1), e123, DOI: 10.3989/gya.0495151.
  56. Hasanloo T., Khavari-Nejab R., Majidi E., Shams-Ardekani M., 2005. Analysis of flavonolignans in dried fruits of Silybum marianum (L.) Gaertn. from Iran. Pak. J. Biol. Sci. 8 (12), 1778–1782.
  57. Hasanloo T., Khavari-Nejad R., Majidi E., Shams Ardakani M., 2008. Flavonolignan production in cell suspension culture of Silybum marianum. Pharmac. Biol. 46(12), 876–882.
  58. Hevia F., Wilckens R., Berti M., Fischer S., 2007. Quality of milk thistle (Silybum marianum [L.] Gaertn.) harvested in different phenological stages. Inf. Technol. 18(5), 69–74.
  59. Hoffmann D., 2016. Ziołowa klinika zdrowia. Fitoterapia dla zdrowego i długiego życia. Inst. Wyd. PAX, Warszawa.
  60. Hogan F., Krishnegowda N., Mikhailova M., Kahlenberg M., 2007. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J. Surg. Res. 143(1), 58–65.
  61. Hussain K., Zia-Ul-Hussain S. Shahazad A., 2010. Distributions and folk tibb knowledge of milk thistle (Silybum marianum L.) in NWFP, Pakistan. Ethnobotanical Leaflets 14, 268–273.
  62. Jamshidi-Kia F., Lorigooini Z., Amini-Khoei H., 2018. Medicinal plants: Past history and future perspective. J. Herbmed. Pharmacol. 7(1), 1–7.
  63. Kalla P.K., Chitti S., Aghamirzaei S.T., Senthilkumar R., Arjunan S., 2014. Anti-cancer activity of silymarin on MCF-7 and NCIH-23 cell lines. Adv. Biol. Res. 8(2), 57–61.
  64. Kamel E., 2004. Cytotaxonomical investigations of the Egyptian Compositae (Asteraceae): I-Cardueae and Cichorieae. Compos. Newsl. 41, 9–28.
  65. Karimi G., Vahabzadeh M., Lari P., Rashedinia M., Moshiri M., 2011. “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran. J. Basic. Med. Sci. 14(4), 308–317.
  66. Karłowicz-Bodalska K., Bodalski T., 2007. Znaczenie surowców roślinnych w leczeniu schorzeń wątroby. Post. Fitoter. 3, 155–167.
  67. Katiyar S., Korman N., Mukhtar H., Agarwal R., 1997. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J. Nat. Cancer Inst. 89(8), 556–565.
  68. Kauntz H., Bousscrouel S., Gosse S., Raul F., 2012. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells. Apoptosis 17(8), 797–809.
  69. Kittur S., Wilasrusmee S., Pedersen W.A., Mattson M.P., Straube-West K., Wilasrusmee C., Jubelt B., Kittur D., 2002. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. J. Mol. Neurosci. 18, 265–269.
  70. Kohlmünzer S., 2007. Farmakognozja. Warszawa, PZWL.
  71. Koksal E., Gülcin I., Beyza S., Sarikaya O., 2009. In vitro antioxidant activity of silymarin. J. Enzym. Inhib. Med. Chem. 24(2), 395–405.
  72. Kren V., Walterova D., 2005. Silybin and silymarin-new effects and applications. Biomed. Papers 149(1) 29–41.
  73. Krepkova L., Sokolskaya T., 2007. Preclinical investigation of the safety on the new hapatoprotective phytopreparation Silymar. Pharmac. Chem. J. 41(9), 486–488.
  74. Kroll D., Shaw H., Oberlies N., 2007. Milk thistle nomenclature: why in matters in cancer research and pharmacokinetic studies. Integr. Cancer Ther. 6(2), 110–119.
  75. Kvasnicka F., Biba B., Sevcik R., Voldrich M., Kratka J., 2003. Analysis of the active components of silymarin. J. Chrom. A. 990, 239–245.
  76. Kwiatkowski J., Szczukowski S., Tworkowski J., 2002. Wybrane zagadnienia z nasiennictwa. UWM Olsztyn, ss. 7.
  77. Kucharski B., 2010. Ostropest plamisty (Silybum marianum L. Gaertn.). W: B. Kołodziej (red.), Uprawa ziół. Poradnik dla plantatorów. PWRiL, Poznań.
  78. Kumar T., Kumar Y.L., Kumar S.I., Kumar A., Tripathi D.K., 2011. Phytochemistry and pharmacological activities of Silybum marianum: A Review. Int. J. Pharm. Phytopharmacol. Res. 1(3), 124–133.
  79. Kurkin V., Zapesochnaya G., Volotsueva A., 2001. Flavolignans of Silybum marianum fruit. Chem. Nat. Compd. 37(4), 315–317.
  80. Kurkin V., 2003. Phenylpropanoids from medicinal plants: distribution, classification, structural analysis, and biological activity. Chem. Nat. Compd. 39, 123–153.
  81. Lea I.L., Narayan M., Barrett J.S., 2007. Analysis and comparison of active constituents in commercial standardizes silymarin extract by liquid chromatography-electrospray ionization mass spectrometry. J. Chrom. B 845, 95–103.
  82. Lee D., Liu Y., 2003. Molecular Structure and Stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (Milk Thistle). J. Nat. Prod. 66(9), 1171–1174.
  83. Lee Y.S., Jang K.A., Cha J.D., 2012. Synergistic antibacterial effect between silibinin and antibiotics in oral bacteria. J. Biomed. Biotechnol Article ID 618081, DOI:10.1155/2012/618081.
  84. Lewandowski A., 1992. Nowe odmiany pieprzowca rocznego i ostropest plamistego. Wiad. Zielar. 6(34), 22–23.
  85. Loguercio C., Federico A., 2003. Oxidative stress in viral and alcoholic hepatitis. Free. Radical. Bio. Med. 34(1), 1–10.
  86. Lutomski J., 2001. Znaczenie ziół w terapii i dietetyce. Post. Fitoter. 2–3, 3–8.
  87. Malekzadech M., Mirmazloum S., Mortazavi S., Panahi M., Angorani H., 2011. Physicochemical properties and oil constituents of milk thistle (Silybum marianum Gaertn. cv. Budakalaszi) under drought stress. J. Med. Plants Res. 5(13), 2886–2889.
  88. Marazzoni P., Bombardelli E., 1995. Silybum marianum (Carduus marianus). Fitoterapia 66(1), 3–42.
  89. Martin R., Lauren D., Smith W., Jensen D., Deo D., Douglas J., 2006. Factors influencing silymarin content and composition in variegated thistle (Silybum marianum). New Zeal. J. Crop. Hort. Sci. 34(3), 239–245.
  90. Martinelli T., Potenza E., Moschella A., Zaccheria F., Benedettelli S., Andrzejewska J., 2016. Phenotypic evaluation of a milk thistle germplasm collection: Fruit morphology and chemical composition. Crop Sci. 56, 1–13.
  91. Martinelli T., Whittaker A., Benedettelli B., Carboni A., Andrzejewska J., 2017. The study of flavonolignan association patterns in fruits of diverging Silybum marianum (L.) Gaertn. chemotypes provides new insights into the silymarin biosynthetic pathway. Phytochemistry 144, 9–18.
  92. Meeran S.M., Katiyar S., Elmets C.A., Katiyar S.K., 2006. Silymarin inhibits UV radiation-induced immunosuppression through augmentation of interleukin-12 in mice. Mol. Cancer Ther. 7, 1660–1668.
  93. Minakhmetov R., Onuchak L., Kurkin V., Avdeeva E., Volotsueva V., 2001. Analysis of flavonoids in Silybum marianum fruit by HPLC. Chem. Nat. Compd. 37(4), 318–321.
  94. Minonzio F., 1988. Modulation of human polymorphonuclear leukocyte function by the flavonoid silybin. Int. J. Tiss. React. 10, 223–231.
  95. Mojgan O., Roya S., 2016. Evaluation of antibacterial activity of silymarin against enteric bacterial pathogens. Int. J. Herb. Med. 4(5), 44–45.
  96. Montgomery A., Adeyeni T., San K., Heuertz R.M., Ezekiel U.R., 2016. Curcumin sensitizes silymarin to exert synergistic anticancer activity in colon cancer cells. J. Cancer 7(10), 1250–1257, DOI: 10.7150/jca.15690.
  97. Nazir N., Karim N., Abdel-Halim H., Khan I., Wadood S.F., Nisar M., 2018. Phytochemicalan analysis, molecular docking and antiamnesic effects of methanolic extract of Silybum marianum (L.) Gaertn. seeds in scopolamine induced memory impairment in mice. J. Ethnopharmacol. 210, 198–208, DOI: 10.1016/j.jep.2017.08.026.
  98. Nencini C., Giorgi G., Micheli L., 2007. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 14, 129–135.
  99. Niedworok J., Jankowska B., Kowalczyk E., Okrój W., 1999. Porównawcze badania nad hepatoprotekcyjnym działaniem bajkaliny i sylimarolu. Herba Pol. 3, 199–204.
  100. Nikbakhit A., Goli S., Kargar M., Ahmadzadeh S., 2011. Effect of humic acid on yield and oil characteristics of Silybum marianum and Cucurbita pepo convar. pepo var. styriaca seeds. Herba Pol. 57(4), 25–32.
  101. Nyiredy S., Samu Z., Szucs Z., Gulacsi K., Kurtan T., Antus S., 2008. New insight into the biosynthesis of flavanolignans in the white-flowered variant of Silybum marianum. J. Chromatogr. Sci. 46, 93–96.
  102. Omar A.A., Hadad G.M., Badr J.M., 2012. First detailed quantification of silymarin components in the leaves of Silybum marianum cultivated in Egypt during different growth stages. Acta Chromatogr. 24(3), 463–474.
  103. Patel N., Joseph C., Corcoran G.B., Ray S.D., 2010. Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol. Appl. Pharm. 245, 143–152.
  104. Pares A., Planas R., Torres M., Caballeria J., Viver J., Acero D., Panes J., Rigau J., Santos J., Rodes J., 1998. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J. Hepatol. 28, 615–621.
  105. Polyak S., Morishima C., Lohmann V., Pal S., Lee D., Liu Y., Graf T., Oberliesf N., 2010. Identification of hepatoprotetive flavonolignans from silymarin. Proc. Nat. Acad. Sci. USA 107(13), 5995–5999.
  106. Poppe L., Petersen M., 2016. Variation in the flavonolignan composition of fruits from different Silybum marianum chemotypes and suspension cultures derived therefrom. Phytochemistry 131, 68–75.
  107. Ptasznik A., 2004. Rola sylimaryny w zapobieganiu i leczeniu chorób wątroby. Post. Fitoter. 4, 189–190.
  108. Pyrzanowska J., Piechal A., Blecharz-Klin K., Widy-Tyszkiewicz E., 2006. Interakcje leków roślinnych stosowanych w chorobach układu pokarmowego. Herba Pol. 52(1/2), 75–96.
  109. Radhika M.I., Ezhilarasan D., Gopinath P., 2016. Antimicrobial efficacy of silymarin and silibinin against oral microorganisms. J. Microbiol. Infect. Dis. 7(3), 139–143.
  110. Radjabian T., Rezazadeh S., Fallah Huseini H., 2008. Analysis of silymarin components in the seed extracts of some milk thistle ecotypes from Iran by HPLC. Iran. J. Sci. Tech. Trans. A. 32(A2), 141–146.
  111. Rafieian-Kopaei M., 2012. Medicinal plants and the human needs. J. Herb. Med. Pharmacol. 1(1), 1–2.
  112. Rahimi S., Hasanloo T., Najafi F., Khavari-Nejad R., 2011. Enhancement of silymarin accumulation using precursor feeding in Silybum marianum hairy root cultures. POJ 4(1), 34–39.
  113. Rai M., Acharya D., Rios J., 2011. Ethnomedicinal plants. CRS Press.
  114. Ram M., Bhan K., Gupta K., Brijesh T., Jamwal U., Pal S., 2005. Variability pattern and correlation studies in Silybum marianum Gaertn. Fitoterapia 76, 143–147.
  115. Raskovic A., Stilinovic N., Kolarovic J., Vasovic V., Vukmirovic S., Mikov M., 2011. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules 16(10), 8601–8613.
  116. Rutkowski L. 2006. Klucz do oznaczania roślin naczyniowych Polski niżowej. Warszawa, Wyd. Nauk. PWN.
  117. Samu Z., Nyiredy S., Baitz-Gacs E., Varga Z., Kurtan T., Dinya Z., Antus S., 2004. Structure elucidation and antioxidant activity of (-)-isosilandrin isolated from Silybum marianum L. Chem. Biodivers. 1(11), 1668–2677.
  118. Sadowska K., 2006. Owoce ostropestu plamistego jako prozdrowotny dodatek do pieczywa. Food Sci. Technol. Qual. 2(47), 290–296.
  119. Sagar S., 2007. Future directions for research on Silybum marianum for cancer patients. Integr. Cancer Ther. 6(2), 166–173.
  120. Sanchez-Sampedro M., Fernandez-Tarrago J., Corchete P., 2005. Enhanced Silymarin accumulation is related to calcium deprivation in cell suspension cultures of Silybum marianum (L.) Gaertn. J. Plant Physiol. 162, 1177–1182.
  121. Schonfeld J., Weisbrod B., Muller M.K. 1997. Silibin, a plant extract with antioxidant and membrane stabilizing properties, protect exocrine pancreas from ciclosporin A toxicity. Cell. Mol. Life Sci. 53(11–12), 917–920.
  122. Seidler-Łożykowska K., 2009. Hodowla i odmiany roślin zielarskich. Hodowla i Nasiennictwo 3, 16–20.
  123. Senderski M., 2007. Prawie wszystko o ziołach. Podkowa Leśna, 476–479.
  124. Sersen F., Vencel T., Annus J., 2006. Silymarin and its components scavenge phenylglyoxylic ketyl radicals. Fitoterapia 77, 525–529.
  125. Shaker E., Mahmoud H., Mnaa S., 2010. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem. Toxicol. 48, 803–806.
  126. Shalan M.G., Mostafa M.S., Hassouna M.M., Hassab El-Nabi S.E., El-Refaie A., 2005. Amelioration of lead toxicity on rat liver with vitamin C and silymarin supplements. Toxicology 206, 1–15.
  127. Sharaf A.A., Bahieldin A., Ibrahim S.A., Abdelsalam A.Z., Khalil A.A., 2011. Biochemical and genetic characterization of 12 Silybum marianum accessions collected from Borg El-Arab, an Egyptian habitat. Func. Plant Sci. Biotechnol. 5(1), 22–29.
  128. Shibano M., Lin A., Itokawa H., Lee K., 2007. Separation and characterization of active flavonolignans of Silybum marianum by liquid chromatography connected with hybrid ion-trap and time-of-flight mass spectrometry (LC0MS/IT-TOF). J. Nat. Prod. 70(9), 1424–1428.
  129. Singh R.P. Agarwal R., 2002. Flavonoid antioxidant silymarin and skin cancer. Antioxid. Redox Sign. 4(4), 655–663.
  130. Strzelecka H., Kowalski J., 2000. Encyklopedia zielarstwa i ziołolecznictwa. Wyd. Nauk. PWN, Warszawa.
  131. Subramaniam S., Vaughn K., Carrier D., Clausen E., 2008. Pretreatment of milk thistle seed to increase the silymarin yield: An alternative to petroleum ether defatting. Biores. Tech. 99, 2501–2506.
  132. Svobodova A., Zdarilova A., Maliskova J., Mikulova H., Walterova D., Vostalova J., 2006. Attenuation of UVA-induced damage to human keranocytes by silymarin. J. Derm. Sci. 46, 21–30.
  133. Szałek E., Grześkowiak E., Bełcikowska I., Daraszkiewicz M., Kusek R., 2006. Wybrane interakcje farmakokinetyczne Silybum marianum z innymi lekami. Herba Pol. 52(3), 82–83.
  134. Świdwińska-Gajewska A.M., Czerczak S., 2017. Nanozłoto – działanie biologiczne i dopuszczalne poziomy narażenia zawodowego. Med. Pracy 68(4), 545–556.
  135. Toklu H., Tunali-Akbay T., Erkanli G., Yuksel M., Ercan F., 2007. Silymarin, the antioxidant component of Silybum marianum, protects against burn-induced oxidative skin injury. Burns 33. 908–916.
  136. Van Wyk B., Wink M., 2008. Rośliny lecznicze świata. MedPharm Polska,Wrocław.
  137. Vargas-Mendoza N., Madrigal-Santillán E., Morales-González A., Esquivel-Soto J., Esquivel-Chirino C., García-Luna y González-Rubio M., Gayosso-de-Lucio J.A., Morales-González J.A., 2014. Hepatoprotective effect of silymarin. World J. Hepatol. 6(3), 1444–1449.
  138. Voroneanu L., Nistor I., Dumea R., Apetrii M., Covic A., 2016. Silymarin in type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. J. Diabetes Res. Article ID 5147468, DOI: 10.1155/2016/5147468.
  139. Wagoner J., Negash A., Kane O., Martinez L.E., Nahmias Y., Bourne N., Owen D.M., Grove J., Brimacombe C., McKeating J.A., Pecheur E.I., Graf T.N., Oberlies N.H., Lohmann V., Cao F., Tavis J.E., Polyak S.J., 2010. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51, 1912–1921.
  140. Wallace S., Vaughin K., Stewart B., Viswanathan T., Clausen E., Nagarajan S., Carrier., 2008. Milk thistle extracts inhibit the oxidation of low-density lipoprotein (LDL) and subsequent scavenger receptor-dependent monocyte adhesion. J. Agric. Food Chem. 56, 3966–3972.
  141. Wang X., Xia H., Xing F., Deng G., Shen Q., Zeng S., 2009. A highly sensitive and robust UPLC-MS with electrospray ionization method for quantitation of taxifolin in rat plasma. J. Chrom. B. 877, 1778–1786.
  142. Wesołowska O., Łania-Pietrzak B., Kużdżał M., Stańczak K., Mosiądz D., Dobryszycki P., Ożyhar A., Komorowka M., Hendrich A., Michalak K., 2007. Influence of silybin on biophysical properties of phospholipid bilayers. Act. Pharmac. Sin. 28(2), 296–306.
  143. Wojdyło A., Oszmiański J., Czemerys R., 2007. Antioxidant activity and phenolic compounds in 32 selected herbs. Food Chem. 105, 940–949.
  144. Wolski T., Baj T., Ludwiczuk A., 2003. Uwagi o współczesnej fitoterapii. Ekstrakty i preparaty roślinne w dermatologii. Panacea 4(5), 20–24.
  145. Won D.H., Kim L.H., Jang B., Yang I.H., Kwon H.J., Jin B., Oh S.H., Kang J.H., Hong S.D., Shin J.A., Cho S.D., 2018. In vitro and in vivo anti-cancer activity of silymarin on oral cancer. Tumor Biol. 1–11, DOI: 10.1177/1010428318776170, journals.sagepub.com/home/tub.
  146. Yah C.S., 2013. The toxicity of gold nanoparticles in relation to their physiochemical properties. Biomed. Res. 24(3), 400–413.
  147. Yang S.H., Lin, J.K., Chen W.S., Chiu, J.H., 2003. Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. J. Surg. Res. 113, 133–138.
  148. Zań R., Roliński Z., Kowalski C., Burmańczuk A., 2013. Leczenie toksycznych uszkodzeń wątroby u psów i kotów przy użyciu antyoksydantów. Życie Wet. 88(5), 392–395.
  149. Zarban A., Masood Z., 2008. Evaluation of antioxidant properties of silymarin and its potential to inhibit peroxyl radical in vitro. Pak. J. Pharm. Sci. 21(3), 249–254.
  150. Zheljazkov V., Zhalnov I., Nedkov N., 2006. Herbicides for weed control in Blessed Thistle (Silybum marianum). Weed Tech. 20, 1030–1034.
  151. Zholobenko A., Modriansky M., 2014. Silymarin and its constituents in cardiac preconditioning. Fitoterapia 97, 122–132.

Downloads

Download data is not yet available.

Inne teksty tego samego autora

1 2 3 4 > >> 

Podobne artykuły

1 2 3 4 5 6 7 8 9 > >> 

Możesz również Rozpocznij zaawansowane wyszukiwanie podobieństw dla tego artykułu.